About the study
Pfizer is developing an influenza vaccine based on the mRNA platform and is seeking 25,000 volunteers to participate in the Phase 3 trial to help learn if the vaccine is safe and can help the body produce antibodies that can help fight off the flu.
All participants will receive either the Pfizer investigational mRNA flu vaccine or the current standard dose quadrivalent flu vaccine.
The trial lasts approximately 6 months and requires 3 visits to our clinic. Enrollment for those 65 years of age and older has begun. Enrollment for those age 18-64 begins in November.
Eligible participants are compensated for their time: $150 stipend for visits and $5 for weekly e-diary completion for a total of approximately $500.
Your participation in this research study will help advance a potential mRNA flu vaccine and also support vaccine development for other infectious diseases.